Nearly 12% of Americans Have Tried GLP-1 Based Weight Loss Medications

Nearly 12% of Americans have used GLP-1 medications like Ozempic for weight loss. The use is most common among women aged 50-64, with the drugs gaining popularity due to proven effectiveness and notable side effects such as nausea and diarrhea.
A recent study by RAND Corporation reveals that approximately 12% of the adult population in the United States has used GLP-1 receptor agonist drugs for weight reduction purposes. These medications, including well-known drugs like Ozempic, have gained popularity due to their significant role in facilitating weight loss, especially after numerous studies demonstrated their effectiveness. The survey examined a representative sample of 8,793 Americans, finding that about 11.8% have directly used these drugs, while another 14% expressed interest in trying them. Interestingly, usage rates vary across different demographics, with women aged 50 to 64 exhibiting the highest utilization. Among individuals aged 65 and above, the use was slightly higher in men, whereas women aged 30 to 49 were more than twice as likely to have taken these medications compared to their male counterparts.
The survey also highlighted common side effects experienced by users, predominantly nausea and diarrhea, affecting roughly half and one-third of the users, respectively. Since 2020, prescriptions for GLP-1 drugs have more than tripled, reflecting their rising prominence in weight management strategies. The increasing adoption of these drugs aligns with growing evidence of their efficacy in significant weight reduction, making them a cornerstone in contemporary obesity treatment.
Conducted during April and May of 2025, the study forms part of the largest and most recent research efforts to understand the extent of GLP-1 drug use in the U.S. This trend underscores a shift in weight loss approaches and highlights the importance of understanding both the benefits and side effects associated with these medications. The findings also point towards a demographic skew, with women in middle age leading the adoption of GLP-1 therapies.
Authors of the report include Robert Bozick, Shannon Donofry, and Katherine M. Rancaño, providing valuable insights into the evolving landscape of obesity treatment. This research emphasizes the growing influence of pharmacological solutions in weight management and the importance of monitoring side effects for safe use.
For further details, visit source.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Customized Deep Brain Stimulation Enhances Gait in Parkinson's Disease Patients
Innovative personalized deep brain stimulation techniques are showing promise in improving walking and gait stability in Parkinson's disease patients, leading to better mobility and quality of life.
Innovative Personalized Cancer Vaccines Show Promise in Reducing Tumor Recurrence in Mouse Models
University of Wisconsin–Madison researchers have developed personalized cancer vaccines that target tumor remnants, significantly reducing recurrence in mouse models and offering new hope for highly aggressive cancers.
Long COVID linked to Extended and Heavier Menstrual Bleeding
Research shows that Long COVID is associated with longer and heavier menstrual bleeding, without impairing ovarian function. The study explores mechanisms behind menstrual disturbances in affected individuals.



